• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Poll

POLL: How Many People in the US Have Generalized Pustular Psoriasis?

Author(s):

Dermatology Times Staff

Click here to answer this week's poll.

How many people in the US have generalized pustular psoriasis?

<5,000
>10,000
<500
>800

Related Videos
Related Content
FDA Gives Go-Ahead on Quoin Pharmaceuticals’ QRX003 Netherton Syndrome Study
December 19th 2024

FDA Gives Go-Ahead on Quoin Pharmaceuticals’ QRX003 Netherton Syndrome Study

FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa
November 12th 2024

FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa

Benvitimod is Safe for Palmoplantar Pustulosis, New Study Finds
October 29th 2024

Benvitimod is Safe for Palmoplantar Pustulosis, New Study Finds

Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment
August 6th 2024

Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment

Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%
July 29th 2024

Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%

Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita
July 25th 2024

Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita

© 2024 MJH Life Sciences

All rights reserved.